Which has preferable valuation and earnings, HCM or CABA?

HUTCHMED has higher revenue and earnings than Cabaletta Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 3.50 $456.91M N/A N/A Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A

Is HCM or CABA more profitable?

HUTCHMED's return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Cabaletta Bio N/A -131.58% -96.46%

Does the media favor HCM or CABA?

In the previous week, HUTCHMED and HUTCHMED both had 3 articles in the media. HUTCHMED's average media sentiment score of 1.06 beat Cabaletta Bio's score of 0.97 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ATAI or CABA?

In the previous week, Atai Beckley had 9 more articles in the media than Cabaletta Bio. MarketBeat recorded 12 mentions for Atai Beckley and 3 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.97 beat Atai Beckley's score of 0.65 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CABA or BCAX?

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is CABA or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% Bicara Therapeutics N/A -35.89% -33.78%

Does the media prefer CABA or BCAX?

In the previous week, Bicara Therapeutics had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 4 mentions for Bicara Therapeutics and 3 mentions for Cabaletta Bio. Bicara Therapeutics' average media sentiment score of 1.64 beat Cabaletta Bio's score of 0.97 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CABA or PGEN more profitable?

Cabaletta Bio has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% Precigen -646.99% 717.50% 58.48%

Does the media prefer CABA or PGEN?

In the previous week, Cabaletta Bio and Cabaletta Bio both had 3 articles in the media. Cabaletta Bio's average media sentiment score of 0.97 beat Precigen's score of 0.62 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CABA or ZYME more profitable?

Cabaletta Bio has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% Zymeworks -126.92% -37.97% -25.31%

Cabaletta Bio (CABA) Competitors

$2.69 -0.03 (-1.10%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.70 +0.01 (+0.37%)

As of 07/24/2026 07:34 PM Eastern

Compare

CABA vs. HCM, ATAI, BCAX, PGEN, and ZYME

Should you buy Cabaletta Bio stock or one of its competitors? MarketBeat compares Cabaletta Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cabaletta Bio include HUTCHMED (HCM), Atai Beckley (ATAI), Bicara Therapeutics (BCAX), Precigen (PGEN), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry.

How does Cabaletta Bio compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

HUTCHMED has higher revenue and earnings than Cabaletta Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.50	$456.91M	N/A	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

In the previous week, HUTCHMED and HUTCHMED both had 3 articles in the media. HUTCHMED's average media sentiment score of 1.06 beat Cabaletta Bio's score of 0.97 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.8% of HUTCHMED shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

HUTCHMED presently has a consensus target price of $14.87, suggesting a potential upside of 35.03%. Cabaletta Bio has a consensus target price of $15.50, suggesting a potential upside of 476.21%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

HUTCHMED has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market.

HUTCHMED's return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Cabaletta Bio	N/A	-131.58%	-96.46%

Summary

HUTCHMED beats Cabaletta Bio on 7 of the 12 factors compared between the two stocks.

How does Cabaletta Bio compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Cabaletta Bio (NASDAQ:CABA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Atai Beckley has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.26, indicating that its share price is 226% more volatile than the broader market.

Cabaletta Bio has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Cabaletta Bio	N/A	-131.58%	-96.46%

Cabaletta Bio has lower revenue, but higher earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$3.49M	757.87	-$660.05M	-$2.23	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

In the previous week, Atai Beckley had 9 more articles in the media than Cabaletta Bio. MarketBeat recorded 12 mentions for Atai Beckley and 3 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.97 beat Atai Beckley's score of 0.65 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atai Beckley currently has a consensus price target of $11.38, indicating a potential upside of 58.54%. Cabaletta Bio has a consensus price target of $15.50, indicating a potential upside of 476.21%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.31
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

28.4% of Atai Beckley shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cabaletta Bio beats Atai Beckley on 9 of the 16 factors compared between the two stocks.

How does Cabaletta Bio compare to Bicara Therapeutics?

Cabaletta Bio (NASDAQ:CABA) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

In the previous week, Bicara Therapeutics had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 4 mentions for Bicara Therapeutics and 3 mentions for Cabaletta Bio. Bicara Therapeutics' average media sentiment score of 1.64 beat Cabaletta Bio's score of 0.97 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicara Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cabaletta Bio presently has a consensus price target of $15.50, indicating a potential upside of 476.21%. Bicara Therapeutics has a consensus price target of $30.27, indicating a potential upside of 12.04%. Given Cabaletta Bio's higher possible upside, equities analysts clearly believe Cabaletta Bio is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Cabaletta Bio has a beta of 3.26, meaning that its stock price is 226% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.81, meaning that its stock price is 181% less volatile than the broader market.

Bicara Therapeutics' return on equity of -35.89% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Summary

Bicara Therapeutics beats Cabaletta Bio on 8 of the 12 factors compared between the two stocks.

How does Cabaletta Bio compare to Precigen?

Cabaletta Bio (NASDAQ:CABA) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Cabaletta Bio presently has a consensus price target of $15.50, suggesting a potential upside of 476.21%. Precigen has a consensus price target of $12.50, suggesting a potential upside of 131.48%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Cabaletta Bio is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Cabaletta Bio and Cabaletta Bio both had 3 articles in the media. Cabaletta Bio's average media sentiment score of 0.97 beat Precigen's score of 0.62 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio has a beta of 3.26, suggesting that its stock price is 226% more volatile than the broader market. Comparatively, Precigen has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

Cabaletta Bio has higher earnings, but lower revenue than Precigen. Precigen is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Precigen	$9.68M	198.88	-$250.64M	-$1.18	N/A

Cabaletta Bio has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Precigen	-646.99%	717.50%	58.48%

33.5% of Precigen shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cabaletta Bio beats Precigen on 8 of the 14 factors compared between the two stocks.

How does Cabaletta Bio compare to Zymeworks?

Cabaletta Bio (NASDAQ:CABA) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

92.9% of Zymeworks shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cabaletta Bio had 2 more articles in the media than Zymeworks. MarketBeat recorded 3 mentions for Cabaletta Bio and 1 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.89 beat Cabaletta Bio's score of 0.97 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Overall Sentiment
Cabaletta Bio	Positive
Zymeworks	Very Positive

Zymeworks has higher revenue and earnings than Cabaletta Bio. Zymeworks is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Zymeworks	$105.96M	15.75	-$81.13M	-$1.37	N/A

Cabaletta Bio currently has a consensus target price of $15.50, indicating a potential upside of 476.21%. Zymeworks has a consensus target price of $37.33, indicating a potential upside of 63.31%. Given Cabaletta Bio's higher possible upside, research analysts plainly believe Cabaletta Bio is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Cabaletta Bio has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Zymeworks	-126.92%	-37.97%	-25.31%

Cabaletta Bio has a beta of 3.26, meaning that its share price is 226% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Summary

Zymeworks beats Cabaletta Bio on 11 of the 16 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CABA vs. The Competition

Export

Metric	Cabaletta Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$443.51M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.37	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.08	89.50
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	2.32	7.88	10.28	6.07
Net Income	-$167.86M	$23.86M	$3.60B	$331.99M
7 Day Performance	-4.95%	-3.82%	-1.27%	-0.63%
1 Month Performance	-7.88%	-2.61%	-0.37%	-2.00%
1 Year Performance	62.05%	32.79%	18.30%	13.62%

Cabaletta Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CABA Cabaletta Bio	2.3039 of 5 stars	$2.69 -1.1%	$15.50 +476.2%	+62.0%	$443.51M	N/A	N/A	50	Positive News
HCM HUTCHMED	2.7579 of 5 stars	$11.14 +0.6%	$15.30 +37.3%	-38.1%	$1.93B	$548.51M	N/A	1,796	News Coverage Positive News Upcoming Earnings Analyst Forecast
ATAI Atai Beckley	3.1989 of 5 stars	$4.97 -3.9%	$15.50 +211.9%	+92.0%	$1.90B	$4.09M	N/A	80	Analyst Revision
BCAX Bicara Therapeutics	2.1722 of 5 stars	$28.15 -2.6%	$30.27 +7.5%	+126.5%	$1.90B	N/A	N/A	32	News Coverage Positive News
PGEN Precigen	3.0774 of 5 stars	$5.17 -2.8%	$12.50 +141.8%	+237.5%	$1.90B	$9.68M	N/A	190

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CABA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cabaletta Bio (CABA) Competitors

CABA vs. HCM, ATAI, BCAX, PGEN, and ZYME

How does Cabaletta Bio compare to HUTCHMED?

Summary

How does Cabaletta Bio compare to Atai Beckley?

Summary

How does Cabaletta Bio compare to Bicara Therapeutics?

Summary

How does Cabaletta Bio compare to Precigen?

Summary

How does Cabaletta Bio compare to Zymeworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cabaletta Bio (CABA) Competitors

CABA vs. HCM, ATAI, BCAX, PGEN, and ZYME

How does Cabaletta Bio compare to HUTCHMED?

Which has preferable valuation and earnings, HCM or CABA?

Does the media favor HCM or CABA?

Do insiders & institutionals believe in HCM or CABA?

Do analysts rate HCM or CABA?

Which has more risk and volatility, HCM or CABA?

Is HCM or CABA more profitable?

Summary

How does Cabaletta Bio compare to Atai Beckley?

Which has more risk & volatility, ATAI or CABA?

Is ATAI or CABA more profitable?

Which has better earnings and valuation, ATAI or CABA?

Does the media refer more to ATAI or CABA?

Do analysts recommend ATAI or CABA?

Do institutionals & insiders have more ownership in ATAI or CABA?

Summary

How does Cabaletta Bio compare to Bicara Therapeutics?

Which has preferable valuation & earnings, CABA or BCAX?

Does the media prefer CABA or BCAX?

Do analysts prefer CABA or BCAX?

Which has more volatility and risk, CABA or BCAX?

Is CABA or BCAX more profitable?

Summary

How does Cabaletta Bio compare to Precigen?

Do analysts prefer CABA or PGEN?

Does the media prefer CABA or PGEN?

Which has more volatility and risk, CABA or PGEN?

Which has preferable earnings & valuation, CABA or PGEN?

Is CABA or PGEN more profitable?

Do institutionals & insiders hold more shares of CABA or PGEN?

Summary

How does Cabaletta Bio compare to Zymeworks?

Do insiders & institutionals have more ownership in CABA or ZYME?

Does the media refer more to CABA or ZYME?

Which has preferable valuation and earnings, CABA or ZYME?

Do analysts rate CABA or ZYME?

Is CABA or ZYME more profitable?

Which has more volatility and risk, CABA or ZYME?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools